Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Epidermal growth factor receptor inhibition in aerodigestive carcinomas

This week's Journal of the American Medical Association investigates epidermal growth factor receptors as therapeutic targets in aerodigestive carcinomas.

News image

fiogf49gjkf04

Malignancies arising from the aerodigestive epithelium, including lung, head and neck, and esophageal carcinomas, are the leading causes of cancer-related mortality worldwide.

The biological importance of epidermal growth factor receptor in cancer development and progression has been established.

Because of this, epidermal growth factor receptor inhibitors have emerged as promising novel therapies.

Dr Michalis Karamouzis and colleagues from Pennsylvania, USA summarized the current status of epidermal growth factor receptor inhibitors in aerodigestive carcinomas.

The team have highlighted ongoing research designed to optimize their therapeutic effectiveness, and consider the future role of these agents.

The research team performed a systematic MEDLINE search of English-language literature 1966 to 2007.

Multiple epidermal growth factor receptor inhibition strategies are under evaluation
Journal of the American Medical Association

The team used the terms epidermal growth factor receptor, epidermal growth factor receptor inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors.

Search terms including lung cancer, head and neck cancer, esophageal cancer, and epidermal growth factor receptor predictive factors were also used.

Quality assessment of selected studies included clinical pertinence.

To minimize bias, the team considered controlled study design, and publication in peer-reviewed journals.

Adequate number of enrolled patients, objectivity of measurements, and techniques used were also assessed by the researchers.

The team found that the role of the epidermal growth factor receptor in aerodigestive carcinomas pathogenesis has been extensively studied.

The researchers observed that multiple epidermal growth factor receptor inhibition strategies are under evaluation.

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used as a single agent has shown survival benefit in 1 trial of patients with advanced non-small cell lung cancer.

The team noted that cetuximab, an anti- epidermal growth factor receptor monoclonal antibody used in combination with radiation, has also conferred survival benefit in 1 trial of patients with locally advanced head and neck squamous cell carcinoma.

However, other trials have not shown these degrees of improvement.

Epidermal growth factor receptor inhibitors toxicities include rash, diarrhea, and hypomagnesemia.

Somatic mutations and other molecular tumoral characteristics offer opportunities for treatment individualization and optimal patient selection for anti-epidermal growth factor receptor therapy.

Dr Karamouzis' team commented, "Epidermal growth factor receptor is a promising therapeutic target in aerodigestive carcinomas."

"Further translational research is needed to optimize ways of inhibiting epidermal growth factor receptor using single-agent or combination regimens and to identify patients who benefit the most from these therapies."

JAMA 2007: 298(1): 70-82
05 July 2007

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us